Summary
The patients’ persistence with osteoporosis treatments is low. This retrospective, multicenter survey showed that almost 30% of osteoporotic patients discontinued the treatment within the first 6 months and that those taking drinkable bisphosphonates were less likely to interrupt the therapy; instead, the use of generic bisphosphonates was associated to a more precocious interruption.
Gonnelli, S., Caffarelli, C., Letizia Mauro, G. et al. Retrospective evaluation of persistence in osteoporosis therapy with oral bisphosphonates in Italy: the TOBI study. Aging Clin Exp Res 31, 1541–1547 (2019). https://doi.org/10.1007/s40520-019-01205-7